1046079-80-4

Basic information

• Product Name: 2-(1-benzylpiperidin-4-yl)-1,3,4-oxadiazole
• Synonyms: 2-(1-benzylpiperidin-4-yl)-1,3,4-oxadiazole
• CAS NO: 1046079-80-4
• Molecular Formula: C₁₄H₁₇N₃O
• Molecular Weight: 243.30428
• Mol File: 1046079-80-4.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(1-benzylpiperidin-4-yl)-1,3,4-oxadiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1-benzylpiperidin-4-yl)-1,3,4-oxadiazole(1046079-80-4)
• EPA Substance Registry System: 2-(1-benzylpiperidin-4-yl)-1,3,4-oxadiazole(1046079-80-4)

Safety Data

• Hazardous Substances Data: 1046079-80-4(Hazardous Substances Data)

Usage

Chemical structure

The compound consists of a piperidine ring with a benzyl group attached to it, and an oxadiazole moiety.

Type of compound

It is a heterocyclic compound.

Pharmaceutical applications

It has potential pharmaceutical applications due to the presence of the piperidine ring and oxadiazole moiety, which are commonly found in many drugs and possess various pharmacological properties.

Pharmacological properties

The oxadiazole moiety has been shown to possess antibacterial, antifungal, and anti-inflammatory activities.

Potential uses

The compound has the potential to be used in the development of new therapeutic agents for various medical conditions.

Importance of synthesis and study

The synthesis and study of this compound could contribute to the discovery of new drugs with improved pharmacological profiles.

Upstream product

• 74045-91-3 1-benzyl-piperidine-4-carboxylic acid hydrazide 
• 122-51-0 orthoformic acid triethyl ester 

Relevant articles and documents

Synthesis of GABAA receptor agonists and evaluation of their α-subunit selectivity and orientation in the GABA binding site

Drugs used to treat various disorders target GABAA receptors. To develop α subunit selective compounds, we synthesized 5-(4-piperidyl)-3-isoxazolol (4-PIOL) derivatives. The 3-isoxazolol moiety was substituted by 1,3,5-oxadiazol-2-one, 1,3,5-oxadiazol-2-thione, and substituted 1,2,4-triazol-3-ol heterocycles with modifications to the basic piperidine substituent as well as substituents without basic nitrogen. Compounds were screened by [3H]muscimol binding and in patch-clamp experiments with heterologously expressed GABAA αiβ 3γ2 receptors (i = 1-6). The effects of 5-aminomethyl-3H-[1,3,4]oxadiazol-2-one 5d were comparable to GABA for all α subunit isoforms. 5-piperidin-4-yl-3H-[1,3,4]oxadiazol-2-one 5a and 5-piperidin-4-yl-3H-[1,3,4]oxadiazol-2-thione 6a were weak agonists at α2-, α3-, and α5-containing receptors. When coapplied with GABA, they were antagonistic in α2-, α4-, and α6-containing receptors and potentiated α3-containing receptors. 6a protected GABA binding site cysteine-substitution mutants α1F64C and α1S68C from reacting with methanethiosulfonate-ethylsulfonate. 6a specifically covalently modified the α1R66C thiol, in the GABA binding site, through its oxadiazolethione sulfur. These results demonstrate the feasibility of synthesizing α subtype selective GABA mimetic drugs.